An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Study Summary

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.

Conditions

Non-small Cell Lung Cancer

Interventions / Drugs

Cemiplimab Platinum-based chemotherapy

View on ClinicalTrials.gov ↗

Sponsor

REGN

Regeneron Pharmaceuticals

Antibody Therapeutics

F34/100

Study Details

Enrollment500 participants

Primary Completion—

Lead SponsorRegeneron Pharmaceuticals

Data Retrieved2026-04-11 02:55:54.866476+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.